Interleukin Genetics

Belkins
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. The products empower individuals and their healthcare providers to manage prevention and treatment of chronic diseases through genetics-based insights and actionable guidance. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program and its Inherent Health® line of genetic tests.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences | June 01, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

news image

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

news image

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

news image

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More
news image

ANIXA BIOSCIENCES AND ONTOCHEM HAVE SYNTHESIZED FOUR POTENTIAL COVID-19 DRUGS FOR TESTING IN BIOLOGICAL ASSAYS

Anixa Biosciences | June 01, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 (https://ir.anixa.com/press-releases/detail/947/) and announced discovery of its first potential Covid-19 cand...

Read More
news image

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More
news image

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More
news image

INDUSTRIAL IMPACT

SKYLINEDX RAISES NEW CAPITAL FROM NOVALIS LIFESCIENCES AND VAN HERK INVESTMENTS

SkylineDx | December 22, 2021

SkylineDx announced it received a capital investment from USA based investment and advisory firm Novalis LifeSciences, and one of Benelux' largest biotech investors Van Herk Investments, to further solidify its position in the USA dermatology diagnostics market. SkylineDx is at a critical growth stage in their development now that the first products are introduced to the USA market, and Novalis LifeSciences has demonstrated impressive successes with their strategic and operational advi...

Read More